Clinical trial
A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)
NCT04396756 is registered in ClinicalTrials.gov with Pliant Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)
- Lead sponsor
- Pliant Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 3, 2020
- Completion date
- February 15, 2023
- Enrollment
- 120 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.